{
    "Trade/Device Name(s)": [
        "BD BBL Sensi-Disc Cefiderocol 30\u03bcg (FDC-30)",
        "BD BBL Sensi-Disc Antimicrobial Susceptibility Test (AST) Discs"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K221826",
    "Predicate Device Reference 510(k) Number(s)": [
        "K193504"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "JTN"
    ],
    "Summary Letter Date": "December 21, 2022",
    "Summary Letter Received Date": "June 23, 2022",
    "Submission Date": "June 20, 2022",
    "Regulation Number(s)": [
        "21 CFR 866.1620"
    ],
    "Regulation Name(s)": [
        "Antimicrobial Susceptibility Test Disc"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Cefiderocol"
    ],
    "Specimen Type(s)": [
        "Gram-negative bacteria (e.g., Escherichia coli, Enterobacter cloacae complex, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Acinetobacter baumannii complex, Serratia marcescens, Citrobacter freundii complex, Citrobacter koseri, Klebsiella aerogenes, Klebsiella oxytoca, Morganella morganii, Proteus vulgaris, Providencia rettgeri)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD BBL Sensi-Disc Dispenser"
    ],
    "Method(s)/Technology(ies)": [
        "Semi-quantitative agar diffusion",
        "Kirby-Bauer Disk Diffusion Susceptibility Test"
    ],
    "Methodologies": [
        "Agar diffusion susceptibility testing",
        "Zone diameter measurement"
    ],
    "Submission Type(s)": [
        "Disc",
        "Antimicrobial susceptibility test"
    ],
    "Document Summary": "FDA 510(k) summary for BD BBL Sensi-Disc Cefiderocol 30\u03bcg antimicrobial susceptibility test disc for in vitro testing of Gram-negative bacteria using agar diffusion methodology",
    "Indications for Use Summary": "Used in the semi-quantitative agar diffusion method for in vitro susceptibility testing of Cefiderocol against Gram-negative bacteria causing complicated urinary tract infections (including pyelonephritis) and hospital-acquired or ventilator-associated bacterial pneumonia",
    "fda_folder": "Microbiology"
}